BUPRENORPHINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Buprenorphine is the first medication to treat opioid use disorder that may be prescribed or distributed in doctor's offices, vastly expanding access to care. Buprenorphine should be prescribed as a component of a thorough treatment plan that includes counseling and other services to give patients a whole-person approach, as is the case with all drugs used in therapy. Buprenorphine provides a number of benefits for those with opioid use disorder and for those for whom therapy at an opioid treatment center is uncomfortable or inappropriate.

The following buprenorphine products are approved for the treatment of opioid use disorder by the U.S. FDA:

• Generic buprenorphine/naloxone sublingual tablets
• Buprenorphine sublingual tablets (Subutex)
• Buprenorphine/naloxone sublingual films (Suboxone)
• Buprenorphine/naloxone sublingual tablets (Zubsolv)
• Buprenorphine/naloxone buccal film (Bunavail)
• Buprenorphine implants (Probuphine)
• Buprenorphine extended-release injection (Sublocade)

Market Dynamics

Increasing approval of buprenorphine by regulatory authorities for subcutaneous use is expected to increase the global buprenorphine market over the forecast period. For instance, in March, 2018, Indivior PLC, a pharmaceutical company, announced that SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII), is available in the U.S. The U.S. Food and Drug Administration (FDA) has granted approval for the use of SUBLOCADE for the treatment of moderate to severe opioid use disorder (OUD) in adult patients who have started therapy with a transmucosal buprenorphine-containing medication and have undergone dose titration for at least seven days. It should only be given by medical professionals, and it should be part of a comprehensive treatment plan that also includes counseling and psychosocial support.

Key features of the study

• This report provides in-depth analysis of the global buprenorphine market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global buprenorphine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Mallinckrodt, Noramco, Unichem Laboratories Ltd., Sanofi, Johnson Matthey, Arevipharma Gmbh, Resonance Laboratories Pvt. Ltd., Sun Pharmaceutical Industries Limited, Rusan Pharma Ltd. Micro Orgo Chem, Faran Shimi Pharmaceutical, Indivior PLC, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global buprenorphine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global buprenorphine market

Market Segmentation

• Brand Insights (Revenue, USD Mn, 2021 - 2033)
  • Sublocade (buprenorphine extended‐release)
  • Suboxone (buprenorphine and naloxone)
  • Brixadi (buprenorphine extended‐release)
  • Zubsolv (buprenorphine and naloxone)
  • Others (Belbuca, Butrans and among others)
• Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Branded
  • Generics
• Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
  • Injectable
    • Intravenous
    • Intramuscular
    • Subcutaneous
  • Sublingual
  • Buccal
  • Transdermal
  • Others
• Dosage Form Insights (Revenue, USD Mn, 2021 - 2033)
  • Injectable Solutions
  • Patches
  • Films
  • Others (Tablets, etc.)
• Indication Insights (Revenue, USD Mn, 2021 - 2033)
  • Opioid Use Disorder (OUD)
  • Pain Management
  • Acute Pain
  • Chronic Pain
• Formulation Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Single Drug Formulation
  • Fixed Dose Combination
• Age Group Insights (Revenue, USD Mn, 2021 - 2033)
  • Adults
  • Pediatric
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Indivior
  • Braeburn
  • Camurus
  • Collegium Pharmaceutical
  • Teva Pharmaceuticals
  • Hikma Pharmaceuticals USA
  • Alvogen
  • Camber Pharmaceuticals
  • Apotex
  • Dr Reddy’s Laboratories
  • Orexo
  • Rusan Pharma
  • Arevipharma
  • Noramco
  • Neuraxpharm